Published in J Immunother on June 24, 2010
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood (2014) 1.09
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs (2011) 0.95
Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm (2013) 0.93
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res (2016) 0.93
Bi-specific aptamers mediating tumor cell lysis. J Biol Chem (2011) 0.87
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. MAbs (2012) 0.87
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol (2016) 0.84
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84
γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay. Front Immunol (2014) 0.81
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget (2014) 0.81
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther (2016) 0.81
NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. J Transl Med (2013) 0.80
DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies. Front Genet (2015) 0.78
Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. Expert Opin Biol Ther (2016) 0.76
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. J Cancer Res Clin Oncol (2015) 0.75
Role of Natural Killer Cells in HIV-Associated Malignancies. Front Immunol (2017) 0.75
New approaches for the immunotherapy of acute myeloid leukemia. Discov Med (2015) 0.75
Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J (2017) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16]. J Cancer Res Clin Oncol (2017) 0.75
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol (2003) 3.80
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 2.64
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2006) 2.20
Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood (2014) 1.80
Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. J Leukoc Biol (2006) 1.75
AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model (2005) 1.69
Life hung by a thread: endurance of Antarctic fauna in glacial periods. Ecology (2008) 1.63
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2005) 1.58
CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. Brain Behav Immun (2007) 1.48
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood (2006) 1.45
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res (2008) 1.43
Intra-articular morphine for inflammatory pain. Reg Anesth Pain Med (2006) 1.41
Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood (2004) 1.40
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol (2003) 1.36
Hypomorphic mutations in PGAP2, encoding a GPI-anchor-remodeling protein, cause autosomal-recessive intellectual disability. Am J Hum Genet (2013) 1.34
Contamination of perilymph sampled from the basal cochlear turn with cerebrospinal fluid. Hear Res (2003) 1.33
Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest (2008) 1.27
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol (2010) 1.25
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Induction of maturation and cytokine release of human dendritic cells by Helicobacter pylori. Infect Immun (2004) 1.21
Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. J Med Chem (2009) 1.18
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res (2005) 1.17
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther (2009) 1.16
Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood (2010) 1.13
Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol (2006) 1.11
Subcellular pathways of beta-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. Endocrinology (2003) 1.10
Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun (2004) 1.10
Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol (2012) 1.09
Characterization of the immunoregulatory function of human TCR-αβ+ CD4- CD8- double-negative T cells. Eur J Immunol (2011) 1.09
Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev (2007) 1.09
Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients. Anesthesiology (2004) 1.09
Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells. FASEB J (2006) 1.09
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol (2010) 1.08
Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res (2007) 1.07
Rational Molecular Design and EPC Synthesis of a Type VI beta-Turn Inducing Peptide Mimetic This work was supported by the BMBF and the Fonds der Chemischen Industrie. EPC=enantiomerically pure compound. Angew Chem Int Ed Engl (2001) 1.06
Different mechanisms of intrinsic pain inhibition in early and late inflammation. J Neuroimmunol (2003) 1.06
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J Immunol (2012) 1.04
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother (2011) 1.04
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother (2008) 1.03
Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res (2003) 1.01
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood (2007) 1.01
High-resolution alkenone palaeobarometry indicates relatively stable pCO(2) during the Pliocene (3.3-2.8 Ma). Philos Trans A Math Phys Eng Sci (2013) 1.01
Impact of Helicobacter pylori virulence factors and compounds on activation and maturation of human dendritic cells. Infect Immun (2005) 1.00
Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res (2014) 1.00
Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J Neuroimmunol (2002) 0.99
Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells. Pain (2004) 0.99
An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods (2002) 0.99
In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother (2008) 0.99
Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report. J Med Case Rep (2011) 0.98
Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol (2007) 0.97
Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res (2006) 0.97
Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C. Mol Pain (2007) 0.97
Mobilization of opioid-containing polymorphonuclear cells by hematopoietic growth factors and influence on inflammatory pain. Anesthesiology (2004) 0.97
Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood (2004) 0.96
Tissue monocytes/macrophages in inflammation: hyperalgesia versus opioid-mediated peripheral antinociception. Anesthesiology (2004) 0.96
Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. J Neurosci (2006) 0.96
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res (2008) 0.95
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs (2011) 0.95
Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci (2004) 0.95
Characterization of the Helicobacter pylori cysteine-rich protein A as a T-helper cell type 1 polarizing agent. Infect Immun (2005) 0.95
Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils. PLoS Pathog (2009) 0.95
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother (2007) 0.95
Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain--basic and therapeutic aspects. Brain Behav Immun (2009) 0.95
Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94
Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain. J Pharmacol Exp Ther (2003) 0.94
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer (2011) 0.94
Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (2007) 0.93
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol (2010) 0.93
Leukocyte-derived opioid peptides and inhibition of pain. J Neuroimmune Pharmacol (2006) 0.93
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer (2010) 0.93